Let the restructuring of Takeda begin now.
The Japanese pharma company is selling off its end of a Chinese marketing and R&D joint venture for $280 million. That’s not much cash for Takeda right now, which is taking on a heavy debt load as it pushes ahead with plans to buy Shire for $62 billion.
But everything helps.
Takeda’s rummage sale starts with its 51.34% stake in Guangdong Techpool Bio-Pharma Co (Techpool), which is engaged in “the research, discovery and marketing of urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care.”
Takeda is selling the stake to its JV partner, Shanghai Pharmaceutical Holding Co., and a fund managed by SFund International Investment Fund Management Limited, a subsidiary of Guangzhou Industrial Investment Fund Management.
Look for plenty of more spinouts and sales once the Shire deal goes through and Takeda looks to slim down to a more leanly focused biopharma organization. The deals are just beginning, and Shanghai Pharma sounds content with the buyout.
“This acquisition marks a strategic milestone for Shanghai Pharma in developing into a branded pharmaceutical manufacturer, and in building a first-class, domestic marketing organization,” commented Shanghai Pharma chairman Zhou Jun. “We believe via acquisitions such as this, and our overall strategy, Shanghai Pharma has an important role to play in the China government’s ‘Healthy China’ policy.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription